Literature DB >> 31294445

Loss of Cln5 leads to altered Gad1 expression and deficits in interneuron development in mice.

Yajuvinder Singh1, Henri Leinonen1,2, Feroze Fazaludeen1, Merja Jaronen1, Debbie Guest3, Noel Buckley4, Nadiya Byts5, Petra Oksa1, Kari Jalkanen1, Imran Iqbal1, Mikko Huuskonen1, Ekaterina Savchenko1, Velta Keksa-Goldsteine1, Sweelin Chew1, Johanna Myllyharju5, Heikki Tanila1, Lezanne Ooi6, Jari Koistinaho1,7, Katja M Kanninen1, Tarja Malm1.   

Abstract

The Finnish-variant late infantile neuronal ceroid lipofuscinosis, also known as CLN5 disease, is caused by mutations in the CLN5 gene. Cln5 is strongly expressed in the developing brain and expression continues into adulthood. CLN5, a protein of unknown function, is implicated in neurodevelopment but detailed investigation is lacking. Using Cln5-/- embryos of various ages and cells harvested from Cln5-/- brains we investigated the hitherto unknown role of Cln5 in the developing brain. Loss of Cln5 results in neuronal differentiation deficits and delays in interneuron development during in utero period. Specifically, the radial thickness of dorsal telencephalon was significantly decreased in Cln5-/- mouse embryos at embryonic day 14.5 (E14.5), and expression of Tuj1, an important neuronal marker during development, was down-regulated. An interneuron marker calbindin and a mitosis marker p-H3 showed down-regulation in ganglionic eminences. Neurite outgrowth was compromised in primary cortical neuronal cultures derived from E16 Cln5-/- embryos compared with WT embryos. We show that the developmental deficits of interneurons may be linked to increased levels of the repressor element 1-silencing transcription factor, which we report to bind to glutamate decarboxylase (Gad1), which encodes GAD67, a rate-limiting enzyme in the production of gamma-aminobutyric acid (GABA). Indeed, adult Cln5-/- mice presented deficits in hippocampal parvalbumin-positive interneurons. Furthermore, adult Cln5-/- mice presented deficits in hippocampal parvalbumin-positive interneurons and showed age-independent cortical hyper excitability as measured by electroencephalogram and auditory-evoked potentials. This study highlights the importance of Cln5 in neurodevelopment and suggests that in contrast to earlier reports, CLN5 disease is likely to develop during embryonic stages.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31294445     DOI: 10.1093/hmg/ddz165

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  6 in total

Review 1.  Endosomal Trafficking in Alzheimer's Disease, Parkinson's Disease, and Neuronal Ceroid Lipofuscinosis.

Authors:  Yasir H Qureshi; Penelope Baez; Christiane Reitz
Journal:  Mol Cell Biol       Date:  2020-09-14       Impact factor: 4.272

Review 2.  A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis.

Authors:  I Basak; H E Wicky; K O McDonald; J B Xu; J E Palmer; H L Best; S Lefrancois; S Y Lee; L Schoderboeck; S M Hughes
Journal:  Cell Mol Life Sci       Date:  2021-04-01       Impact factor: 9.261

Review 3.  More than a Corepressor: The Role of CoREST Proteins in Neurodevelopment.

Authors:  Simon Maksour; Lezanne Ooi; Mirella Dottori
Journal:  eNeuro       Date:  2020-03-10

4.  Aberrant Autophagy Impacts Growth and Multicellular Development in a Dictyostelium Knockout Model of CLN5 Disease.

Authors:  Meagan D McLaren; Sabateeshan Mathavarajah; William D Kim; Shyong Q Yap; Robert J Huber
Journal:  Front Cell Dev Biol       Date:  2021-07-05

5.  Spinal manifestations of CLN1 disease start during the early postnatal period.

Authors:  H R Nelvagal; J T Dearborn; J R Ostergaard; M S Sands; J D Cooper
Journal:  Neuropathol Appl Neurobiol       Date:  2020-09-07       Impact factor: 8.090

Review 6.  Altered protein secretion in Batten disease.

Authors:  Robert J Huber
Journal:  Dis Model Mech       Date:  2021-12-06       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.